This article explores the purpose and scope of DRPs, BCPs, and IRPs, their differences, and how they complement each other.

Of all the risks associated with pharmaceuticals and medical devices, controlling contamination is one of the most important and difficult challenges. Relational risk analysis (ReRA) can help.

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

New Delhi, Feb 5 (IANS) Majority of leaders in life sciences -- pharmaceutical and medical technology companies ... expecting Artificial Intelligence (AI) to drive revenue management in 2025, ...

WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for ...

Pharmaceutical organizations are continually evolving — rapidly. Often, this evolution involves an increased use of third parties. As changes occur, companies’ third-party risk management (TPRM) ...

3. Fund Size: The Nippon India Pharma Fund - Direct Plan currently holds Assets under Management worth of Rs 8914.89 crore as on Dec 31, 2024. 4. Expense ratio: The expense ratio of the fund is 0.92% ...

Risk management is the work of balancing opportunities ... Similarly, successful traders commonly quote the phrase: "Plan the trade and trade the plan." Just like in war, planning ahead can ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...